mifepristone has been researched along with Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Check, DL; Check, JH | 2 |
| Check, D; Check, JH | 2 |
| Chung, I; Godoy, A; Gunasagran, Y; Mat Adenan, NA; Omar, IS; Teo, IH | 1 |
| Ambrosini, G; Andrisani, A; Bordin, L; Conley, J; Marin, L; Sabbadin, C; Vio, C | 1 |
| Li, CJ; Pardee, AB | 1 |
| Brandhagen, BN; Goyeneche, AA; Ritch, SJ; Telleria, CM | 1 |
| Check, D; Check, JH; Lofberg, P; Wilson, C | 1 |
| Check, JH; Dix, E; Sansoucie, L | 1 |
| Check, D; Check, JH; Cohen, R; Dix, E; Wilson, C | 1 |
| Brandhagen, BN; Goyeneche, AA; Ortbahn, CT; Telleria, CM; Tieszen, CR | 1 |
| Brandhagen, BN; Goyeneche, AA; Telleria, CM; Tieszen, CR; Tracy, MS; Ulmer, TM | 1 |
| Watanabe, ME | 1 |
| Case, CC; Dent, CL; Drake, EA; Gregory, PD; Lau, G; Yoon, A | 1 |
| Peyron, R; Silvestre, L; Ulmann, A | 1 |
| Bardin, CW; Spitz, IM | 1 |
| Grunberg, SM | 1 |
| Kalkhoven, E; van der Burg, B; van der Saag, PT; Wissink, S | 1 |
| Bjørge, L; Iversen, OE | 1 |
8 review(s) available for mifepristone and Neoplasms
| Article | Year |
|---|---|
A Hypothetical Model Suggesting Some Possible Ways That the Progesterone Receptor May Be Involved in Cancer Proliferation.
Topics: Antineoplastic Agents, Hormonal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fetus; Gene Expression Regulation; Hormone Antagonists; Humans; Immune Tolerance; Mifepristone; Neoplasms; Placenta; Pregnancy; Pregnancy Proteins; Receptors, Progesterone; Signal Transduction; Suppressor Factors, Immunologic; Tumor Microenvironment | 2021 |
New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Proliferation; Clinical Studies as Topic; Disease Models, Animal; Disease Susceptibility; Drug Discovery; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mifepristone; Molecular Targeted Therapy; Neoplasms; Prognosis; Receptors, Progesterone; Treatment Outcome | 2021 |
The role of progesterone and the progesterone receptor in cancer: progress in the last 5 years.
Topics: Humans; Mifepristone; Neoplasms; Progesterone; Receptors, Progesterone | 2023 |
Fertility preservation in pregnant cancer patients after first-trimester abortion: a new challenge with possible solutions.
Topics: Cryopreservation; Female; Fertility Preservation; Humans; Mifepristone; Neoplasms; Ovulation Induction; Pregnancy; Pregnancy Trimester, First; Progesterone | 2023 |
Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review.
Topics: Animals; Female; Hormone Antagonists; Humans; Killer Cells, Natural; Longevity; Mifepristone; Neoplasms; Palliative Care; Placenta; Pregnancy; Pregnancy Proteins; Progesterone; Progestins; Receptors, Progesterone; Suppressor Factors, Immunologic | 2019 |
Clinical uses of mifepristone (MFP).
Topics: Abortion, Induced; Animals; Cervix Uteri; Clinical Trials as Topic; Contraceptives, Postcoital; Endometriosis; Female; Humans; Hydrocortisone; Labor, Induced; Mifepristone; Misoprostol; Neoplasms; Pregnancy | 1995 |
Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid.
Topics: Abortion, Induced; Animals; Female; Genitalia, Female; Glucocorticoids; Humans; Mifepristone; Molecular Structure; Neoplasms; Pregnancy; Progestins | 1993 |
[Mifepristone--a controversial drug with great potential].
Topics: Abortifacient Agents, Steroidal; Contraceptives, Oral, Synthetic; Female; Genital Diseases, Female; History, 20th Century; Hormone Antagonists; Humans; Labor, Induced; Mifepristone; Neoplasms; Pregnancy; Pregnancy Complications; Receptors, Progesterone | 2001 |
16 other study(ies) available for mifepristone and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Aberrant upregulation of CDK1 contributes to medroxyprogesterone acetate (MPA) resistance in cancer-associated fibroblasts of the endometrium.
Topics: Cancer-Associated Fibroblasts; CDC2 Protein Kinase; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Luciferases; Medroxyprogesterone Acetate; Mifepristone; Neoplasms; Receptors, Progesterone; RNA, Messenger; Up-Regulation | 2022 |
Two controls of cell proliferation underlie cancer relapse.
Topics: Cell Differentiation; Cell Membrane; Cell Proliferation; Chorionic Gonadotropin; HeLa Cells; Humans; Mifepristone; Mutation; Neoplasms; Neoplastic Stem Cells; Prostaglandins; Recurrence; Signal Transduction; Stem Cells; Zygote | 2018 |
Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling.
Topics: Cell Movement; Cell Proliferation; Fluorescence; Hormone Antagonists; Humans; Mifepristone; Neoplasm Invasiveness; Neoplasms; Tumor Cells, Cultured; Wound Healing | 2019 |
Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Hormone Antagonists; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Mifepristone; Neoplasms; Survival Rate | 2016 |
Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein.
Topics: Animals; Disease Models, Animal; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Mice; Mifepristone; Neoplasms; Pregnancy Proteins; Progesterone; Receptors, Progesterone; RNA, Messenger; Suppressor Factors, Immunologic | 2009 |
Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Colonic Neoplasms; Female; Histiocytoma, Malignant Fibrous; Hormone Antagonists; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Mifepristone; Neoplasms; Palliative Care; Pancreatic Neoplasms; Receptors, Progesterone; Survival Rate; Thymus Neoplasms; Treatment Outcome; Young Adult | 2010 |
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Neoplasms; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone | 2011 |
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cytostatic Agents; Female; Hormone Antagonists; Humans; Male; Mifepristone; Neoplasm Invasiveness; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Time Factors | 2013 |
RU 486: an overview of mifepristone and its potential applications.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Biology; Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptives, Postcoital; Developed Countries; Disease; Embryo Implantation; Endocrine System; Endometrium; Europe; Family Planning Services; France; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Labor Stage, First; Menstruation; Mifepristone; Neoplasms; North America; Ovulation; Physiology; Therapeutics; United States; Urogenital System; Uterus | 1993 |
RU 486 research forges on, despite political hurdles.
Topics: Adrenal Cortex; Americas; Biology; Breast Neoplasms; Central Nervous System; Clinical Trials as Topic; Developed Countries; Disease; Economics; Endocrine Glands; Endocrine System; Evaluation Studies as Topic; Financial Management; Financing, Government; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Mifepristone; Neoplasms; North America; Physiology; Politics; Prejudice; Research; Social Problems; United States; Urogenital System; Uterus | 1994 |
RU 486 approved in Britain; U.S. research still limited.
Topics: Abortifacient Agents; Abortion, Induced; Americas; Biology; Breast Neoplasms; Consumer Product Safety; Developed Countries; Disease; Endocrine System; Europe; Family Planning Services; France; Hormone Antagonists; Hormones; Legislation as Topic; Mifepristone; Neoplasms; North America; Physiology; Prostaglandins; Scandinavian and Nordic Countries; United Kingdom; United States | 1991 |
Who's trying to scare women?
Topics: Abortion, Induced; Americas; Attitude; Behavior; Biology; Breast Neoplasms; Canada; Contraception; Developed Countries; Disease; Endocrine System; Evaluation Studies as Topic; Family Planning Services; Hormone Antagonists; Hormones; Jurisprudence; Mifepristone; Neoplasms; North America; Physiology; Politics; Psychology; Public Opinion; United States | 1996 |
Regulation of endogenous gene expression using small molecule-controlled engineered zinc-finger protein transcription factors.
Topics: Animals; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Regulation; Genetic Engineering; Genetic Therapy; Green Fluorescent Proteins; Hormone Antagonists; Humans; Mice; Mifepristone; Neoplasms; Receptors, Progesterone; Time Factors; Transcription Factor RelA; Transcription Factors; Vascular Endothelial Growth Factor A; Zinc Fingers | 2007 |
Methotrexate and misoprostol to terminate early pregnancy.
Topics: Abortifacient Agents; Abortion, Induced; Female; Humans; Methotrexate; Mifepristone; Misoprostol; Neoplasms; Pregnancy | 1996 |
Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor.
Topics: Animals; Base Sequence; Cell Line; Cytokines; DNA Primers; Female; Gene Expression Regulation; HeLa Cells; Humans; Immune Tolerance; Mifepristone; Molecular Sequence Data; Neoplasms; NF-kappa B; Phosphorylation; Pregnancy; Pregnancy Maintenance; Progesterone; Progestins; Receptors, Progesterone; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 1996 |